Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
SAT0400 REAL-WORLD SWITCH RATES AMONG BIOLOGIC-NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST, TUMOR NECROSIS FACTOR INHIBITORS OR INTERLEUKIN INHIBITORS — David Kaplan (2019) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
SAT0400 REAL-WORLD SWITCH RATES AMONG BIOLOGIC-NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST, TUMOR NECROSIS FACTOR INHIBITORS OR INTERLEUKIN INHIBITORS
DK
Shared by
David Kaplan
SAT0400 REAL-WORLD SWITCH RATES AMONG BIOLOGIC-NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST, TUMOR NECROSIS FACTOR INHIBITORS OR INTERLEUKIN INHIBITORS
Article
2019
en
Authors
+2 more
DK
David Kaplan
BU
Brian Ung
CP
Corey Pelletier
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2019
PMS37 RATES OF REAL-WORLD TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE
David Kaplan
,
Benjamin S.‐Y. Ung
,
Corey Pelletier
,
Chuka Udeze
,
M. Tian
Article
2019
PSS15 REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
David Kaplan
,
Benjamin S.‐Y. Ung
,
C. Udeze
,
C. Pelletier
,
M. Tian
Article
2021
Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis
David Kaplan
,
Brian Ung
,
Corey Pelletier
,
Chuka Udeze
,
Ibrahim Khilfeh
,
Marc Tian
Dataset
Supplementary material: Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis
David Kaplan
,
Brian Ung
,
Corey Pelletier
,
Chuka Udeze
,
Ibrahim Khilfeh
,
Marc Tian
Article
2019
PSS14 REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
David Kaplan
,
Benjamin S.‐Y. Ung
,
Corey Pelletier
,
Chuka Udeze
,
M. Tian
Discussion(0)
No comments yet. Be the first to comment.